iBio price target raised to $6 from $5 at Oppenheimer

Oppenheimer analyst Jay Olson raised the firm’s price target on iBio (IBIO) to $6 from $5 and keeps an Outperform rating on the shares. The firm notes shares were up 8% vs. flat XBI, basking in well-deserved attention for IBIO-610 following updates from WVE’s INHBE-targeting siRNA WVE-007. In its Phase 1 INLIGHT trial, WVE-007 elicited up to about 85% activin E reduction, surpassing the preclinical 70% activin E reduction threshold for potential 6-month weight loss comparable to semaglutide.